The aims of this study were to investigate the effect of a novel synthetic anthraquinone compound, LuHui Derivative (LHD, chemical name: 1,8-dihydroxy-3-(hydroxymethyl)-anthraquinone ethyl succinate), against hyperlipidemia-induced cardiomyocyte inflammation and to reveal the underlying molecular mechanisms of the modification of FTO and CD36. Here, CD36 is linked to hyperlipidemia.